Other Clinical Trial - ALI/ARDS Clinical Sub-phenotyping Study

Status Not yet recruiting

Clinical Trial Summary

1. Construct a structured clinical data and biosample information platform for Chinese patients with acute lung injury/ acute respiratory distress syndrome. 2. By deciphering the heterogeneity of patients with acute lung injury/ acute respiratory distress syndrome, achieve clinical, longitudinal physiological, and biological sub-phenotyping to guide individualized precision treatment and improve prognosis.

Clinical Trial Description

Acute lung injury/ acute respiratory distress syndrome is one of the most common and complex critical illnesses in clinical practice, with a high mortality rate of 45% to 50%. Currently, effective therapeutic strategies for this condition are still lacking. Increasing evidence suggests that the significant heterogeneity of this disease plays a crucial role in the poor treatment outcomes and high mortality rates observed in patients. Therefore, this study aims to analyze the heterogeneity of acute lung injury/ acute respiratory distress syndrome patients and establish a clinical classification system for acute lung and extrapulmonary organ injuries. The objectives of this study include establishing a nationwide clinical database and biobank for acute lung injury / acute respiratory distress syndrome by collecting clinical data and biological samples from various provinces. By overcoming the barriers posed by diverse and heterogeneous data sources, mathematical and machine learning models will be utilized to construct clinical, physiological, and biological classification systems for acute lung and extrapulmonary organ injuries. The proposed classification model will be validated multiple times using international public databases and prospective acute lung injury/acute respiratory distress syndrome cohorts to ensure its stability and generalizability. The mapping relationship between different classifications and patient prognosis as well as treatment responsiveness will be explored. Moreover, a machine learning-based supervised technique will be applied to develop a bedside simplified model (Point-of-Care model) and establish a bedside clinical classification decision system. Ultimately, this research aims to provide a foundation for standardized and precision-guided clinical diagnostic and therapeutic pathways, promoting improved treatment outcomes and overall prognosis in acute lung injury/ acute respiratory distress syndrome. ;

Study Design

Related Conditions & MeSH terms

Acute Lung Injury
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Lung Injury
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Syndrome

Clinical Trial Details

NCT number	NCT06123962
Study type	Observational
Source	China-Japan Friendship Hospital
Contact	Jingen Xia, M.D
Phone	+8613466396561
Email	13466396561@163.com
Status	Not yet recruiting
Phase
Start date	December 20, 2023
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05807802` - FSTL1 and PPCs on Pediatric Within LDLT:a Prospective Cohort Analysis
Recruiting	`NCT05002478` - Infants With Severe Acute Respiratory Distress Syndrome: The Prone Trial	N/A
Recruiting	`NCT05153525` - Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS	Phase 4
Completed	`NCT04389671` - The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)	Phase 2
Not yet recruiting	`NCT06147674` - Evaluation of VQm PHM on Pulmonary Health Parameters for ICU
Completed	`NCT04607434` - Mechanism of Delayed Neutrophil Apoptosis in Acute Lung Injury
Completed	`NCT04381338` - Rehabilitation for People With COVID-19 in ICU	N/A
Terminated	`NCT04360096` - Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19	Phase 2/Phase 3
Withdrawn	`NCT05137795` - Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19	Phase 3
Recruiting	`NCT04935697` - Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress	N/A
Withdrawn	`NCT04482712` - Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS	Phase 1/Phase 2
Not yet recruiting	`NCT05343338` - Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium	N/A
No longer available	`NCT04355494` - SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.